Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q2 FY26
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Earkart Limited focuses on manufacturing and distributing affordable hearing aids and accessories, emphasizing innovation and technology integration.
The company has developed the Earkart OMNI, a remote audiometry device that facilitates hearing tests across remote locations, drastically improving accessibility to audiological services.
Despite witnessing a 5.37% drop in H1FY26 revenue due to deferred government orders, Earkart expects a strong rebound, supported by upcoming order executions in the latter half of the fiscal year.
Their strategic expansion includes increasing their shop-in-shop clinics across India while also targeting international markets such as the US and Australia, showcasing global growth ambitions.
The company's entry into the Forbes DGEMS 2025 Select 200 highlights its high-impact potential and global business capabilities in the healthcare technology sector.
Healthcare Equipment & Supplies
Medical Equipment & Supplies
193 Cr
High Risk
21.3
29.1
0.1
3.0
265.95
120.00
Sales CAGR
Profit CAGR
ROE
ROCE
Earkart Limited (EARKART) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Earkart Limited focuses on manufacturing and distributing affordable hearing aids and accessories, emphasizing innovation and technology integration. The company has developed the Earkart OMNI, a remote audiometry device that facilitates hearing tests across remote locations, drastically improving accessibility to audiological services. Despite witnessing a 5.37% drop in H1FY26 revenue due to deferred government orders, Earkart expects a strong rebound, supported by upcoming order executions in the latter half of the fiscal year. Their strategic expansion includes increasing their shop-in-shop clinics across India while also targeting international markets such as the US and Australia, showcasing global growth ambitions. The company's entry into the Forbes DGEMS 2025 Select 200 highlights its high-impact potential and global business capabilities in the healthcare technology sector.
Over the past 52 weeks, Earkart Limited has traded between a low of ₹120.00 and a high of ₹265.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Earkart Limited has a market capitalization of approximately 193.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Earkart Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 193.24 Cr, Earkart Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Earkart Limited operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Earkart Limited is 21.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
46
Bullish
0
Bearish
0
Neutral
32
Bullish
0
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
112.50 | 274 Cr | 28.92 | 3.03 | 0.00 | 8.72 | 11.88 | 6.94 | |
268.70 | 248 Cr | 23.70 | 1.25 | 0.00 | 2.07 | 3.00 | 4.74 | |
140.50 | 193 Cr | 21.32 | 2.99 | 0.00 | 0.00 | 0.00 | 6.95 | |
82.00 | 163 Cr | 12.11 | 1.55 | 0.00 | 11.69 | 14.39 | 6.57 | |
161.00 | 86 Cr | 13.61 | 2.75 | 0.00 | 22.63 | 27.31 | 15.57 | |
151.70 | 84 Cr | 18.45 | 2.49 | 0.00 | 8.55 | 12.66 | 11.21 | |
56.55 | 81 Cr | 9.23 | 1.62 | 0.00 | 0.00 | 0.00 | -1.10 | |
| Median: 7 Co. | 140.50 | 163 Cr | 18.45 | 2.49 | 0.00 | 8.55 | 11.88 | 6.94 |
Board Meeting Outcome
Earkart's board (11 Mar 2026) approved acquisition of land for a manufacturing facility and acquisition of a pharmaceutical business, and clarified the meeting was convened on shorter notice with apology for delayed SEBI intimation.
Board Meeting Outcome
On 11 Mar 2026 Earkart Ltd's Board approved acquisition of land for a manufacturing facility and the acquisition of a pharmaceutical business; the company clarified the meeting was held on shorter notice and apologized for delayed intimation.
